Life Science Nation Newsletter  |  January 22, 2015  |  Issue 95

  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Accelerator
Life Science Investor Mandates (Jan. 12 - Jan. 21)

Seeking Global Opportunities in Brain Health

Seeking Clinical Stage Therapeutics and Device Opportunities Throughout North America

Seeking Healthcare IT and Wearable Device Opportunities
In This Issue

RESI 4 San Francisco: Compelling Connections Created, Dialogues Begun, the Game's Afoot 

Winners Announced for the RESI Innovation Challenge


LSN Videos
UMass Boston MKT465 Sales and Marketing 
RESI Partnering Platform Demo
RESI 2014 Fall, Fenway Park
RESI 3 Family Office Panel
RESI 3 Outbound Fundraising Panel 
RESI 3 Corporate Venture Capital Panel
The Life Science Executive's Fundraising Manifesto
RESI 4 San Francisco: Compelling Connections Created, Dialogues Begun, the Game's Afoot

By Dennis Ford, Founder & CEO, LSN  


Last week, LSN moved its Redefining Early Stage Investment (RESI) Conference series from Boston to San Francisco to partake in the annual migratory life science industry gathering. I am happy to report that RESI 4 was a success.  Attendees included over 200 early stage investors, 200 early stage biotech and medtech entrepreneurs and 100 service providers participating in early stage funding panels, partnering and workshops. Forbes made mention of RESI in their coverage of the JPM Healthcare event.


The big news is not the size of RESI, but the two compelling constituencies that attended and helped to create such a unique and dynamic event.  The first constituency consists of the 10 categories of global investors attending including angel groups, corporate venture capital, foundations, family office and private wealth funds, government organizations, hedge funds, institutional alternative investors, large pharma and medtech companies, private equity firms and venture capital funds. The second constituency, the scientist-entrepreneurs from the biotech and medtech arena, are all actively fundraising and therefore want to be as efficient as possible with their efforts. These fundraising CEOs not only need to meet with investors that are a fit for their stage and sector, but also understand the current investor landscape and how best to navigate within it. Take a look at the program guide and you will understand why RESI is a success and why we are garnering the attention of the industry...

Winners Announced for the RESI Innovation Challenge
By Nono Hu, Senior Manager, Branding & Messaging, LSN


At LSN's fourth Redefining Early Stage Investments (RESI) Conference, 31 selected medtech and biotech companies participated in a virtual investment contest: The RESI Innovation Challenge. RESI Innovators showcased cutting-edge life science technologies in poster displays throughout the exhibit hall, competing to raise the most RESI Cash.


The winners are in. Congratulations!


First Prize Winner: Kineta



Kineta is a nationally-recognized biotechnology company focused on developing leading edge therapeutics in three large high need therapeutic areas: autoimmune disease, viral disease and chronic pain. The company is focused on the development of novel drug candidates, each the outcome of years of scientific exploration and supported by an extensive body of peer-reviewed, NIH-supported research. 


As a first prize winner, Kineta will receive complimentary subscription to the LSN Investor Platform.



Second Prize Winner: Transverse Medical




Transverse Medical, Inc. is an early stage medical technology company in the evolving and rapidly growing area of Transcatheter Aortic Valve Replacement (TAVR). The TAVR procedure, along with other cardiovascular interventional and surgical procedures, is in need of cerebral protection options. TMI is meeting this need and the challenge of preventing neurocognitive stroke events during TAVR and other such procedures through development of the Point-Guard™ Cerebral Embolic Protection Device. 



Third Prize Winner: Amorphex Therapeutics




Amorphex Therapeutics was founded in 2010 to develop and license products for sustained ophthalmic drug delivery using the TODDD™ technology developed by Vista Scientific, LLC. The TODDD™ technology platform is an ocular insert for sustained delivery of drugs to the eye. This patented insert is based on controlled delivery polymer systems and a unique product design utilizing advanced comfort and stability features. In addition to the matrix materials that are used for controlled delivery, the TODDD™ device is also able to incorporate relatively large drug depots for the delivery of specific drugs. This affords the ability to deliver multiple drugs simultaneously...